SAN DIEGO--(BUSINESS WIRE)--Aethlon Medical, Inc., (OTCBB:AEMD) announced today that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for its patent application (10/760,810) entitled, “Method for Removal of Viruses from Blood by Lectin Affinity Hemodialysis.” The claims underlying the patent reinforce the proprietary nature of the Aethlon Hemopurifier® as a potential treatment for a broad-spectrum of infectious disease targets. The patent includes thirteen claims associated with the immobilization of lectins around porous hollow-fiber membranes as a method to remove viruses and toxic viral particles from blood. Lectins are carbohydrate-binding proteins recently discovered to bind a wide range of infectious viruses. Aethlon disclosed that all claims have been allowed, and expects the patent to issue within three to four months after payment of the USPTO issuance fee.
